Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen SARS-CoV-2 Primer Panel for NGS

Qiagen has launched the QiaSeq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome. The panel provides optimized, single-day workflows to prepare libraries for sequencing as researchers use NGS to study the epidemiology of virus outbreaks. The two-step process applies QiaSeq technologies to conduct reverse transcription and cDNA synthesis from viral RNA samples, followed by generation of libraries compatible with Illumina sequencers. The workflow is faster and has lower input requirements than hybrid captures solutions, Qiagen said. The panel is supported with software pipelines tailored to SARS-CoV-2 genome analysis using Qiagen's CLC Genomics Workbench.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.